Citations

Mayo Clinic

Showing 10 of 108602 citations.

Fraction of Osteocalcin Endothelial Progenitor Cells and Cardiovascular Risk
Ӧzcan, Ilke , Kanaji, Yoshihisa , Rajotia, Arush , Toya, Takumi , Akhiyat, Nadia , Morse, David , Lerman, Lilach O. , Lerman, Amir , Ozcan, Ilke , Lerman, Amir , Toya, Takumi , Morse, David , Kanaji, Yoshihisa

Circulation Research | March 29, 2023 | Volume: 132 | Issue: 9 | Pages: 1162-1164

10.1161/circresaha.122.322407 | PMID 36987925 Get It

Under (back) pressure: Better collateral flow may facilitate clot removal in ischemic stroke: A systematic review and meta-analysis
Seymour, Trey , Kobeissi, Hassan , Ghozy, Sherief , Kadirvel, Ramanathan , Kallmes, David F. , Kadirvel, Ram , Kallmes, David F , Ghozy, Sherief , Seymour, Trey J , Kobeissi, Hassan , Gupta, Rishabh

Interventional Neuroradiology | March 29, 2023 | Volume: 32 | Issue: 3 | Pages: 706-712

10.1177/15910199231166739 | PMID 36987690 Get It

Background Collateral status may facilitate clot removal and affect rates of successful reperfusion following endovascular therapy (EVT) for acute ischemic stroke (AIS). Methods Following the PRISMA guidelines, a systematic literature review of the English language literature was conducted using PubMed, Scopus, Web of Science, and Embase. Papers which focused on collateral status and patients treated with EVT for AIS were included in our analysis. Outcomes of interest included collateral score grading, rates of successful reperfusion defined as thrombolysis in cerebral infarction (TICI) score 2b-3 and onset to revascularization time. We calculated pooled odds ratio (OR) or mean difference (MD) and their corresponding 95% confidence intervals (CI) based on collateral status. Results 16 studies, with 6073 patients, were included in our analysis. Among the included studies, there were six different collateral grading scales, which were dichotomized into “good to moderate” and “poor” collaterals. Odds of successful reperfusion were significantly higher among patients with good to moderate collateral circulation compared to those with poor collaterals (OR = 1.61; 95% CI = 1.24 to 2.09; P -value < 0.001); however, there was heterogeneity among included studies (I2 = 5 4%; P -value = 0.008). Onset to revascularization time was comparable between patients with good to moderate collateral circulation compared to those with poor collaterals (MD = 3.91 min; 95% CI = −8.71 to 16.53; P -value = 0.544); however, there was heterogeneity among included studies (I2= 60%; P -value = 0.014). Conclusions The presence of good collaterals may increase the odds of achieving successful reperfusion following EVT for AIS. Improved collateral flow was associated with improved angiographic outcomes, although future work is needed to determine if a causal relationship exists.
Clinical Course of Patients with Hypertrophic Cardiomyopathy Away from Tertiary Referral Care
Garmany, Ramin , Bos, J. Martijn , Ommen, Steve R. , Ackerman, Michael J. , Geske, Jeffrey B. , Bos, Johan M , Geske, Jeffrey B , Garmany, Ramin

ESC Heart Failure | March 29, 2023 | Volume: 10 | Issue: 3 | Pages: 1919-1927

10.1002/ehf2.14345 | PMID 36987533 Get It

Abstract Aims Data on the clinical course of hypertrophic cardiomyopathy (HCM) are mainly derived from tertiary HCM centre studies, and knowledge of clinical outcomes of patients leaving specialty care and returning to local physicians is limited due to gaps between clinical encounters or complete loss of follow-up. This survey aims to describe the clinical course of HCM in patients following their evaluation at a tertiary referral centre. Methods and results A comprehensive outcomes survey was developed and sent to 4495 eligible patients with HCM previously evaluated at Mayo Clinic. Questions assessed general well-being, New York Heart Association class, procedures performed, and probable HCM-triggered ventricular arrhythmic events (VAEs) since last visit. In total, 2058 patients (mean age 63 ± 15 years; 42% female) responded to the survey covering a total of 10 510 patient-years with an average of 5.4 ± 6.4 years of follow-up since their last on-campus/virtual visit to Mayo Clinic. During their time away from specialty care, 20% of patients reported having cardiac-related hospitalizations and 25% reported having cardiac-related procedures. Similar to high-risk referral cohorts, 5% of patients reported VAEs with an event rate of 0.98 events/100 patient-years. The prevalence of atrial fibrillation, syncope, pre-syncope, cardiac-related hospitalizations, and VAEs during time away from specialty care increased significantly with increasing New York Heart Association class (P &lt; 0.001). Conclusions Acknowledging ascertainment bias, the clinical course of patients away from tertiary care may be more severe than previously anticipated. Among those with exertional symptoms, HCM-related morbidity increased substantially. Higher risk HCM patients should remain in contact with HCM specialty care.
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma
Heater, Natalie Knox , Okuno, Scott H. , Attia, Steven , Seetharam, ­Mahesh , Yoon, Janet, Chawla, Sant P. , Milhem, Mohammed , Monga, Varun , Skubitz, Keith M. , Charlson, John A. , Hirbe, Angela C. , Weiss, Mia C. , Tine, Brian A. Van , Agulnik, Mark , Robinson, Steven, Monga, Varun , Skubitz, Keith , Hirbe, Angela C , Van Tine, Brian A , Agulnik, Mark , Milhem, Mohammed M , Robinson, Steven I. , Siontis, Brittany L.

Journal of Clinical Medicine | March 29, 2023 | Volume: 12 | Issue: 7 | Pages: 2561

10.3390/jcm12072561 | PMID 37048645 Get It

The treatment of sarcoma necessitates a collaborative approach, given its rarity and complex management. At a single institution, multidisciplinary teams of specialists determine and execute treatment plans involving surgical, radiation, and medical management. Treatment guidelines for systemic therapies in advanced or nonresectable soft tissue sarcoma have advanced in recent years as new immunotherapies and targeted therapies become available. Collaboration between institutions is necessary to facilitate accrual to clinical trials. Here, we describe the success of the Midwest Sarcoma Trials Partnership (MWSTP) in creating a network encompassing large academic centers and local community sites. We propose a new model utilizing online platforms to expand the reach of clinical expertise for the treatment of advanced soft tissue sarcoma.
CNS T-Cell Lymphoma Many Years After Hemophagocytic Lymphohistiocytosis
Zhu, Agnes , Itoh, Christopher Y. , Coburn, Ryan P., Lu, Lauren , Mustafa, Rafid , Lu, Lauren Xiaoyuan , Coburn, Ryan P

Neurology | March 28, 2023 | Volume: 101 | Issue: 8 | Pages: 369-370

10.1212/wnl.0000000000207244 | PMID 36977599 Get It

Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)
Boughey, Judy C. , Rosenkranz, Kari M. , McCall, Linda, Haffty, Bruce G. , Cuttino, Laurie W., Kubicky, Charlotte Dai, Le‐Petross, Huong T. , Giuliano, Armando E. , Hahn, Olwen, Boughey, JC , Haffty, Bruce G , Hunt, KK , Carey, Lisa A , Partridge, Ann H , Ballman, Karla V. , Zee, Kimberly J. Van , Hunt, Kelly K. , Carey, Lisa A. , Partridge, Ann H.

Journal of Clinical Oncology | March 28, 2023 | Volume: 41 | Issue: 17 | Pages: 3184-3193

10.1200/jco.22.02553 | PMID 36977292 Get It

PURPOSE Breast-conserving therapy (BCT) is the preferred treatment for unifocal breast cancer (BC). The oncologic safety of BCT for multiple ipsilateral breast cancer (MIBC) has not been demonstrated in a prospective study. ACOSOG Z11102 (Alliance) is a phase II, single-arm, prospective trial designed to evaluate oncologic outcomes in patients undergoing BCT for MIBC. PATIENTS AND METHODS Women age 40 years and older with two to three foci of biopsy-proven cN0-1 BC were eligible. Patients underwent lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds. The primary end point was cumulative incidence of local recurrence (LR) at 5 years with an a priori rate of clinical acceptability of <8%. RESULTS Among 270 women enrolled between November 2012 and August 2016, there were 204 eligible patients who underwent protocol-directed BCT. The median age was 61 years (range, 40-87 years). At a median follow-up of 66.4 months (range, 1.3-90.6 months), six patients developed LR for an estimated 5-year cumulative incidence of LR of 3.1% (95% CI, 1.3 to 6.4). Patient age, number of sites of preoperative biopsy–proven BC, estrogen receptor status and human epidermal growth factor receptor 2 status, and pathologic T and N categories were not associated with LR risk. Exploratory analysis showed that the 5-year LR rate in patients without preoperative magnetic resonance imaging (MRI; n = 15) was 22.6% compared with 1.7% in patients with a preoperative MRI (n = 189; P = .002). CONCLUSION The Z11102 clinical trial demonstrates that breast-conserving surgery with adjuvant radiation that includes lumpectomy site boosts yields an acceptably low 5-year LR rate for MIBC. This evidence supports BCT as a reasonable surgical option for women with two to three ipsilateral foci, particularly among patients with disease evaluated with preoperative breast MRI.
Proposed dietary recommendations for iron overload: a guide for physician practice
Saleh, Hasan , Seaman, Leigh Ann Kenda, Palmer, William C.

Current Opinion in Gastroenterology | March 28, 2023 | Volume: 39 | Issue: 3 | Pages: 146-149

10.1097/mog.0000000000000923 | PMID 36976854 Get It

Purpose of review Iron overload disorders such as hemochromatosis involve unregulated absorption of dietary iron, leading to excessive iron accumulation in multiple organs. Phlebotomy is the standard of care for removal of excess iron, but dietary modification is not standardized in practice. The purpose of this article is to help standardize hemochromatosis diet counseling based on commonly asked patient questions. Recent findings The clinical benefit regarding dietary modification in iron overload patients is limited due to lack of large clinical trials, but preliminary results are promising. Recent studies suggest diet modification could reduce iron burden in hemochromatosis patients resulting in less annual phlebotomy as supported through small patient studies, concepts of physiology, and animal studies. Summary This article is a guide for physicians to counsel hemochromatosis patients based on commonly asked questions such as foods to avoid, foods to consume, use of alcohol, and use of supplements. The goal of this guide is to help standardize hemochromatosis diet counseling to reduce phlebotomy amount in patients. Standardization of diet counseling could help facilitate future patient studies to analyze the clinical significance.
Leuprolide Protects Ovarian Reserve in Adolescents Undergoing Gonadotoxic Therapy
Hoyos-Martínez, Alfonso , Okcu, M. Fatih , Horne, Vincent E. , Allen-Rhoades, Wendy, Scheurer, Michael E. , Allen‐Rhoades, Wendy

Journal of Adolescent and Young Adult Oncology | March 28, 2023 | Volume: 12 | Issue: 6 | Pages: 828-834

10.1089/jayao.2022.0128 | PMID 36976803 Get It

Purpose: Treatment sequelae compromising reproductive health are highly prevalent in childhood cancer survivors, and a main determinant of health and quality of life. Follicular reserve determines ovarian function life span; thus, its preservation is important in the care of female survivors. Anti-Müllerian hormone (AMH) is a biomarker to measure functional ovarian reserve. We aimed to evaluate the effect of leuprolide during gonadotoxic therapy on pubertal females' post-treatment functional ovarian reserve using AMH levels. Methods: We conducted a single-center retrospective study including all pubertal females who had undergone gonadotoxic treatments between January 2010 and April 2020, and had an AMH level after completion of therapy. We used multivariable linear regressions to compare AMH-level beta coefficients in patients stratified by gonadotoxic risk, adjusting for leuprolide use. Results: Fifty-two females meeting study eligibility were included, of which 35 received leuprolide. The use of leuprolide was associated with higher post-treatment AMH levels in the lower gonadotoxic risk group (beta 2.74, 95% CI 0.97–4.51; p = 0.004). This association was lost in the higher gonadotoxic risk groups. Conclusions: Leuprolide may have a protective effect on the functional ovarian reserve. However, this is limited by increasing treatment gonadotoxicity. Larger, prospective studies are needed to elucidate the potential benefits of gonadotropin-releasing hormone agonist on preservation of ovarian reserve among children receiving gonadotoxic therapies, as cancer survivors.
Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam
Vasquez, Alejandra , Youssef, Paul E., Wirrell, Elaine

Expert Review of Neurotherapeutics | March 28, 2023 | Volume: 23 | Issue: 4 | Pages: 297-309

10.1080/14737175.2023.2195550 | PMID 36975187 Get It

Lymphangioleiomyomatosis in lymph node cytology: Another “Floating Island” to visit
Jawaid, Tabinda , Swanson, Amy A. , Bois, Melanie C. , Folpe, Andrew L. , Rivera, Michael , Hartley, Christopher , Sturgis, Charles D. , Hartley, Christopher P., Sturgis, Charles D , Hartley, Christopher P

Diagnostic Cytopathology | March 28, 2023 | Volume: 51 | Issue: 6 | Pages: No page available

10.1002/dc.25131 | PMID 36975549 Get It

AbstractLymphangioleiomyomatosis (LAM) is a rare disease with variable presentations. The neoplastic cells in LAM demonstrate a unique and diagnostically important “myomelanocytic” phenotype. Cytologic reports of LAM are infrequent and have not in the past emphasized the floating island pattern in which circumscribed aggregates of lesional cells are rimmed by appliques of flattened endothelium. This case illustrates the cytology of LAM and emphasizes that the floating island cytoarchitectural pattern more classically associated with entities such as hepatocellular carcinomas may be seen in cytological preparations of LAM at unanticipated body sites.